http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CY-1118400-T1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4afb8b01aa8de7e0b24a86713b23a18 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 |
| filingDate | 2016-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da816b89d02ce210966652f4fe33fe6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fe0b5646f984457f954e0a3982d1bdd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae4a9ee4a8f407a26f53010b10f3b23e |
| publicationDate | 2017-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CY-1118400-T1 |
| titleOfInvention | NMDA SUSPENDED RECEPTORS FOR TREATMENT CELL ANIMAL TREATMENT |
| abstract | Sickle cell anemia is a genetic disease characterized by red blood cells that adopt an abnormal, rigid, sickle shape. Acute complications of sickle cell anemia are coincidentally treated with analgesics and transfusions and a prophylactic treatment of sickle cell crisis is long-term application of hydroxyurea. According to the present invention, an N-methyl D-aspartate receptor (NMDAR) inhibitor is used for the treatment of sickle cell anemia and for the manufacture of a medicament for the treatment of sickle cell anemia. In addition, a method for screening a compound effective in treating sickle cell anemia involves contacting a candidate compound with NMDAR and selecting said candidate compound as effective if found to selectively reduce NMDAR activity. |
| priorityDate | 2009-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.